COVID-19 patient screening questionnaire

Following guidance from the Centers for Disease Control and Prevention (CDC), Quest Diagnostics has developed a simple patient screening guide to help you quickly determine if a patient is at lower risk when you schedule a chronic, acute, or well visit. This model may change as CDC guidelines and US Food & Drug Administration recommendations are updated.

Has the patient been diagnosed as positive for COVID-19 with a molecular (PCR) test in the past 10 days?

Do they have a fever of 100.4°F or greater?

Has the patient had any COVID-19 symptoms (such as fever, cough, shortness of breath) in the last 3 days?

Has the patient been exposed to COVID-19 in the last 14 days?

Healthcare provider consultation, consider molecular testing, and connect to care to determine next steps

Schedule an office visit or telehealth call, and consider antibody testing if requested

For more information on COVID-19, please visit QuestDiagnostics.com/COVID19

The antibody tests (sometimes known as the serology tests or IgG tests) are intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Results are for the detection of SARS-CoV-2 antibodies. IgG antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of time antibodies are present post-infection is not well characterized. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. Individuals may have detectable virus present for several weeks following seroconversion. Negative results do not preclude acute SARS-CoV-2 infection. If acute infection is suspected, molecular testing for SARS-CoV-2 is necessary. The antibody test should not be used to diagnose acute SARS-CoV-2 infection. False positive results for the antibody test may occur due to cross-reactivity from pre-existing antibodies or other possible causes.

• The antibody tests and the molecular tests (together “All tests”) have not been FDA cleared or approved;
• All tests have been authorized by FDA under EUAs for use by authorized laboratories;
• The antibody tests have been authorized only for the detection of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens;
• The molecular tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and,
• All tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

QuestDiagnostics.com